Product Description
Originally isolated from Actinomycetes strain based on its potent in vivo antitumor activity, Epoxomicin is a potent, cell-permeable, selective and irreversible proteasome inhibitor. More potent inhibitor of the chymotrypsin-like activity of the proteasome than Lactacystin (Cat. No. 1709-100). Blocks also trypsin-like and PGPH activities of the proteasome.
Epoxomicin is a potent, cell-permeable, selective and irreversible proteasome inhibitor. More potent inhibitor of the chymotrypsin-like activity of the proteasome than Lactacystin (Cat. No. 1709-100). Blocks also trypsin-like and PGPH activities of the proteasome.
Biovision | 2190 | Epoxomicin DataSheet
Alternate Name/Synonyms: N-acetyl-N-methyl-L-isoleucyl-L-isoleucyl-N-[(1S)-3-methyl- 1-[[(2R)-2-methyloxiranyl]carbonyl]butyl]-L-threoninamide; BU-4061T
Appearance: White solid
Formulation: N/A
CAS Number: 134381-21-8
Structure Available?: Yes
Peptide sequence: N/A
Salt Form: No
Molecular Formula: C₂₈H₅₀N₄O₇
Molecular Weight: 554.7
Cell-Permeable?: Yes
Purity: ≥95% by HPLC
Solubilities: DMSO (~ 10 mg/ml)
Handling: Protect from air and moisture
Country of Origin: USA
Tag Line: A potent proteasome inhibitor
MDL Number: MFCD03791061
PubChem CID: 11226684
SMILES: CCC(C)C(C(=O)NC(C(C)O)C(=O)NC(CC(C)C)C(=O)C1(CO1)C)NC(=O)C(C(C)CC)N(C)C(=O)C
InChi: InChI=1S/C28H50N4O7/c1-11-16(5)21(30-27(38)23(17(6)12-2)32(10)19(8)34)25(36)31-22(18(7)33)26(37)29-20(13-15(3)4)24(35)28(9)14-39-28/h15-18,20-23,33H,11-14H2,1-10H3,(H,29,37)(H,30,38)(H,31,36)/t16-,17-,18+,20-,21-,22-,23-,28+/m0/s1
InChi Key: DOGIDQKFVLKMLQ-JTHVHQAWSA-N